TNF and rheumatoid arthritis: LTBI subjects, due to the increasing use of biological drugs, such as tumor necrosis factor-α (TNF-α)/Interleukin (IL)-12/IL-23 blockers for the treatment of inflammatory diseases like rheumatoid arthritis, Crohn’s disease, and psoriasis, have major risk to progress toward active disease more than other subjects (3, 7).